Get startedLog in
    Picture of Ambrx Biopharma logo

    AMAM — Ambrx Biopharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapHigh Flyer
    All News

    Brief: Ambrx Provides Safety And Efficacy Data From Ongoing Phase 1/2 APEX-01 Trial Of ARX517 in mCRPC At ESMO Congress

    Picture of Ambrx Biopharma logoAmbrx Biopharma
    16/10/2023 14:01
    Oct 16 (Reuters) - Ambrx Biopharma Inc  AMAM.O :
    * AMBRX PROVIDES SAFETY AND EFFICACY DATA FROM ONGOING PHASE
1/2
APEX-01 TRIAL OF ARX517 IN MCRPC AT ESMO CONGRESS
    * AMBRX BIOPHARMA CAYMAN INC - NO DRUG-RELATED SEVERE
ADVERSE
EVENTS (SAES) AND NO DOSE LIMITING TOXICITIES (DLTS) OBSERVED IN
ANY COHORT
    * AMBRX BIOPHARMA CAYMAN INC - NO DRUG-RELATED SEVERE
ADVERSE
EVENTS (SAES) AND NO DOSE LIMITING TOXICITIES (DLTS) OBSERVED IN
ANY COHORT
    * AMBRX BIOPHARMA CAYMAN INC - PHARMACOKINETIC (PK) DATA
INDICATED
STRONG ADC STABILITY PREVENTING PREMATURE RELEASE OF ANTICANCER
PAYLOAD

Source text for Eikon:  ID:nGNX8Pq98B 
Further company coverage:  AMAM.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Ambrx Biopharma

    See all news